Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
Design: This is a prospective, non-blinded, single-center study utilizing a hybrid PET-MR scanner for simultaneous imaging. Participants will be divided into three groups: Healthy subjects (n=6) with normal LVEF for baseline reference. Preoperative patients (n=6) with low LVEF due to ischemic cardiomyopathy undergoing coronary artery bypass grafting (CABG). Post-CABG patients (n=6 at 4-6 months, n=6 at 10-12 months) to evaluate post-surgical changes. Procedures: Undergo HP-13C-MRI and FDG-PET imaging in a single session. Blood samples for metabolic biomarkers (lactate, pyruvate, triglycerides, insulin, glucose). Standard clinical cardiac imaging (Echocardiography, SPECT Myocardial Perfusion Imaging).
⁃ Participants must meet all of the following criteria:
• Age between 20-80 years
• Eligible for MRI, PET, and contrast agents (based on institutional screening protocols)
• Scheduled for CABG (for ischemic cardiomyopathy patients)
• Left ventricular ejection fraction (LVEF) ≤ 40% or clinical indication for myocardial viability assessment
• No history of coronary artery disease or diabetes (for healthy controls)
• Negative pregnancy test (for female participants of childbearing potential)